

Chao Huang¹
 Steven M. Santana²
 He Liu³
 Neil H. Bander³
 Benjamin G. Hawkins^{1*}
 Brian J. Kirby^{2,4}

¹Department of Biomedical Engineering, Cornell University, Ithaca, NY, USA

²Sibley School of Mechanical and Aerospace Engineering, Cornell University, Ithaca, NY, USA

³Department of Urology, Weill Medical College of Cornell University, New York, NY, USA

⁴Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA

Received May 23, 2013

Revised July 21, 2013

Accepted July 24, 2013

Research Article

Characterization of a hybrid dielectrophoresis and immunocapture microfluidic system for cancer cell capture

The capture of circulating tumor cells (CTCs) from cancer patient blood enables early clinical assessment as well as genetic and pharmacological evaluation of cancer and metastasis. Although there have been many microfluidic immunocapture and electrokinetic techniques developed for isolating rare cancer cells, these techniques are often limited by a capture performance tradeoff between high efficiency and high purity. We present the characterization of shear-dependent cancer cell capture in a novel hybrid DEP–immunocapture system consisting of interdigitated electrodes fabricated in a Hele-Shaw flow cell that was functionalized with a monoclonal antibody, J591, which is highly specific to prostate-specific membrane antigen expressing prostate cancer cells. We measured the positive and negative DEP response of a prostate cancer cell line, LNCaP, as a function of applied electric field frequency, and showed that DEP can control capture performance by promoting or preventing cell interactions with immunocapture surfaces, depending on the sign and magnitude of the applied DEP force, as well as on the local shear stress experienced by cells flowing in the device. This work demonstrates that DEP and immunocapture techniques can work synergistically to improve cell capture performance, and it will aid in the design of future hybrid DEP–immunocapture systems for high-efficiency CTC capture with enhanced purity.

Keywords:

Circulating tumor cell / Dielectrophoresis / Immunocapture / Microfluidic / Prostate cancer
 DOI 10.1002/elps.201300242

1 Introduction

Circulating tumor cells (CTCs) are cells that have been shed into the circulatory system from a tumor source, and are believed to contribute to cancer metastasis [1, 2]. The enumeration of CTCs isolated from cancer patient blood samples can serve as a prognostic indicator of cancer and predictor of patient survival [3–6]. In addition, genetic and pharmacological evaluation of CTCs can lead to a better understanding of cancer metastasis as well as improved drug therapies [7–11]. However, CTCs are rare—as few as one cell per 10⁸ blood cells [12, 13]. The only system for detecting CTCs, which is approved by the US Food and Drug Administration, CellSearch[®] (Veridex, LLC), requires immunomagnetic tagging and cell fixation, which inhibits further biological anal-

yses on captured CTCs. Given this drawback, the isolation of viable CTCs from cancer patient blood presents a technical challenge for those who wish to study them.

Researchers have developed a variety of techniques for isolating rare cancer cells from blood [2, 14, 15]. Examples of microfluidic approaches include micropillar arrays [9, 16, 17], chaotic mixers [18, 19], filters [20, 21], and devices with other micro- and nanostructured surfaces [22–26]. Of those techniques that are capable of processing whole blood, immunocapture methods have shown the greatest potential for capturing rare cancer cells with high efficiency (62–95%) [16–19]. Studies that used the epithelial cell-adhesion molecule to capture lung, prostate, pancreatic, and colorectal CTCs have reported a wide range of capture purities (9–67%) [16, 18, 19]. Our group has combined immunospecificity with optimization of cell adhesion and transport mechanisms to create geometrically enhanced differential immunocapture (GEDI) [27], and reported a capture purity of 62% with prostate CTCs by use of a monoclonal antibody, J591, that is highly specific to prostate-specific membrane antigen (PSMA) [17]. The main

Correspondence: Dr. Brian J. Kirby, Sibley School of Mechanical and Aerospace Engineering, Cornell University, 238, Upson Hall, Ithaca, NY 14853, USA
E-mail: kirby@cornell.edu
Fax: +1-607-255-1222

Abbreviations: CTC, circulating tumor cell; GEDI, geometrically enhanced differential immunocapture; IDA, interdigitated array; nDEP, negative DEP; pDEP, positive DEP; PSMA, prostate-specific membrane antigen

Colour Online: See the article online to view Fig. 1 in colour.

*Current address: Dr. Benjamin G. Hawkins, Department of Biomedical, Chemical, and Materials Engineering, San José State University, San José, CA 95192, USA.

contributing factor to CTC capture impurities is the non-specific adhesion of leukocytes to immunocapture surfaces. Thus, although immunocapture techniques typically produce high CTC capture efficiencies from whole blood, capture purity can still potentially be improved to facilitate subsequent biological studies on the CTCs.

While microfluidic immunocapture techniques rely on surface immunological interactions to isolate rare cancer cells, electrokinetic techniques such as dielectrophoresis (DEP) primarily rely on differences in the cell populations' electrical properties [28]. DEP refers to the net migration of polarized particles due to interactions with an electric field gradient, and operates in two regimes: when a particle is more polarizable than its suspending medium, positive DEP (pDEP) occurs and the particle is attracted to stronger field regions; conversely, when a particle is less polarizable than the medium, negative DEP (nDEP) occurs and the particle is repelled from stronger field regions [29, 30]. The sign and magnitude of the DEP force are dictated by the real part of the Clausius–Mossotti factor, which describes the relationship between the electrical properties of the particle and the medium as a function of the applied AC electric field frequency [31]. This relationship forms the basis for the majority of DEP cell separation and isolation techniques [32].

Although numerous microfluidic DEP methods for cancer cell capture in artificial samples exist, there has not been a study that demonstrates DEP capture of viable CTCs from whole blood of cancer patients [14]. A majority of DEP cancer cell isolation techniques use model cancer cell lines spiked in buffer media or diluted blood; such techniques include DEP flow-field fractionation [33–36], insulative and contactless DEP [37–40], and streamline separations using angled electrodes [41–44]. These studies separate cancer cells from other blood constituents based on their differences in DEP response in a specific applied frequency range. This binary separation mechanism makes DEP an attractive tool for cell separation, as DEP requires no biochemical treatment or labeling to achieve high capture efficiency and purity. However, to date, studies using DEP methods for CTC capture have only reported high capture performance for model cancer cell lines spiked in preprocessed blood with concentrations ranging from one cancer cell per 10^4 – 10^6 blood cells [33, 34, 36, 39, 40, 42, 44]. The commercially licensed ApoStream™ (ApoCell) system, which uses DEP flow-field fractionation, has reported capture efficiencies in the range of 50–80% for ovarian and breast cancer cell lines spiked in peripheral blood mononuclear cells with concentrations as low as one cancer cell per 10^6 blood cells, but noted that efficiency decreased after running samples through the system multiple times to increase capture purity [35]. DEP capture performance has also been shown to decrease drastically with concentrations lower than one cancer cell per 10^6 blood cells [33]. Thus, although the use of DEP methods often produces high purities for cell separation, their application for CTC capture from whole blood is currently limited by low throughput and efficiency.

Given that DEP and immunocapture techniques both have unique advantages as well as areas for improvement, the development of a platform capable of high capture efficiency and purity could be facilitated by incorporating both methods [14]. In this study, we characterized the performance of a hybrid DEP–immunocapture system by quantifying cell adhesion to immunocapture surfaces as a function of the local shear stress experienced by cells. This characterization of the shear dependence of immunocapture was performed in a Hele-Shaw flow cell using a prostate cancer cell line, LNCaP, and the monoclonal antibody, J591, which is highly specific to PSMA [45, 46]. We show that, depending on the applied electric field frequency, DEP effects can control the capture performance of prostate cancer cells by attracting them to or repelling them from immunocapture surfaces. To our knowledge, this is the first reported study of a hybrid DEP–immunocapture characterization system for cancer cell capture, and our results inform the design of future hybrid DEP–immunocapture devices for high-purity CTC isolation.

2 Materials and methods

2.1 Hele-Shaw flow cell design

To optimize a microfluidic immunocapture system, the flow conditions that affect cell capture performance must be characterized. Such characterization is often difficult or expensive to perform in typical immunocapture devices, given their 3D topologies, cost of fabrication, and sample processing time. A Hele-Shaw flow cell, depicted in Fig. 1, was designed to facilitate the analysis of flow conditions, specifically shear stress, and its effect on the immunocapture of LNCaPs. The device exhibits Stokes flow owing to its small channel depth and attendant low Reynolds number. As the device's width and length are large, its velocity field is approximately equivalent to a solution of a 2D irrotational, incompressible stagnation point flow [47].

Our Hele-Shaw flow cell is similar to but refined relative to previous designs [46–49]. The device geometry includes sidewalls that are sections of rectangular hyperbolas [47], which replicate the far field of a stagnation flow impinging on the coordinate origin of the hyperbolas. However, because the outlet boundaries of such a stagnation flow are impractical to implement, we use two point outlets [48] and terminate the hyperbolas 10 mm from their coordinate origin (Fig. 1). On the device's central axis, this flow asymptotes to a different stagnation flow, one whose coordinate origin is at the flat terminal wall. This geometry leads to a bilinear variation in shear stress along the length of the device's central axis. Figure 2 shows this variation in shear stress as a function of distance from the entrance to the device's main chamber (i.e. the output of the branching inlet channels).

The Hele-Shaw flow cell allows for characterization of cell adhesion as a function of shear stresses corresponding to those experienced by cells in immunocapture devices [9, 46, 49]. To compare immunocapture performance




Figure 1. Schematic of the Hele-Shaw flow cell and its IDA electrodes with lead connections to an applied voltage ($\pm V$) and ground (GND). Inset images show details of the IDA electrode geometry and fluorescently labeled LNCaPs captured with and without DEP effects on the immunocapture surface immobilized with the antibody J591 at various observation sites (corresponding to a range of shear stresses). Captured cells in each pair of observation windows were enumerated and compared at all observation sites. The main chamber was 30 mm long, with an initial width of $w_0 = 5$ mm at its entrance and a flat wall at its terminal end. The channel height was $48 \mu\text{m}$, and the branching inlet and outlet channels were $156 \mu\text{m}$ wide. The width, w , at any x along the curved channel was $w = -(40\text{mm})w_0/x$, given a coordinate system with an origin 40 mm to the right of the main chamber entrance. The shear stress in the main chamber ranged from 0 to 0.029 Pa, as shown in Fig. 2.

of LNCaPs with and without DEP effects, interdigitated array (IDA) electrodes were fabricated along the length of the Hele-Shaw flow cell on only one side of its central axis (Fig. 1). Branching inlet channels into the main chamber entrance ensure that entering cells are uniformly distributed across the chamber width. Approximately half of LNCaPs in the central axis region flow over the IDA electrodes and are affected by a DEP force when the electrodes are energized, whereas the other half of the cell population is unaffected by DEP. In this way, the immunocapture of LNCaPs with and without DEP effects can be directly compared as a function of shear stress.

2.2 Device fabrication

The Hele-Shaw flow cell was fabricated by bonding a channel defined in PDMS to glass. All photolithography and thin-film deposition work was performed at the Cornell NanoScale Science and Technology Facility (CNF). Device masters were fabricated by spin-coating silicon wafers with MicroChem SU-8 2000 to create a film thickness of $48 \mu\text{m}$. The photoresist was exposed at 12 mW/cm^2 for 40 s using an EV620 Contact Aligner on soft-contact mode, then developed in MicroChem SU-8 Developer for 2 min and rinsed with acetone, isopropyl




Figure 2. Shear stress at the immunocapture surface of the Hele-Shaw flow cell's central axis as a function of distance from the entrance to the main chamber (solid line). Two-dimensional variation in shear stress was calculated from a 2D potential flow simulation using COMSOL Multiphysics®, and a Poiseuille distribution was assumed in the height coordinate. The bilinear variation in shear stress results from the transition between (i) a stagnation flow defined by the sidewall hyperbolas with a theoretical stagnation point 40 mm from the main chamber entrance (dashed line), and (ii) a stagnation flow defined by the flat terminal wall with a stagnation point 30 mm from the main chamber entrance (dotted line), as depicted in Fig. 1.

alcohol, and DI H₂O. The wafers were then coated with 1H,1H,2H,2H-perfluorooctyltrichlorosilane (Sigma-Aldrich) to prevent PDMS adhesion.

IDA electrodes were fabricated using standard lift-off photolithography. Borofloat glass wafers were cleaned with hot piranha solution for 10 min and vapor-primed with hexamethyldisilazane for 30 min. The wafers were then spin-coated with Microposit S1818 photoresist at 3000 rpm for 30 s and baked at 115°C for 90 s. The photoresist was exposed at 12 mW/cm² for 60 s using the EV620 Contact Aligner on soft-contact mode, then developed in Microposit MF-321 for 2 min. Wafers were treated with oxygen plasma at 150 W and 80°C for 60 s, then placed in a CVC SC4500 Combination Thermal/Electron-Gun Evaporator. A 250 nm layer of gold was deposited between 20 nm layers of chromium. Lift-off photolithography was performed in Microposit Remover 1165 for 12 h, after which wafers were diced on a K&S 7100 Dicing Saw. The resulting IDA electrode devices were cleaned with Cyantek Nano-Strip for 20 min immediately before bonding to PDMS.

PDMS was prepared using a Sylgard[®] 184 Silicone Elastomer Kit with a 5:1 ratio of elastomer base to curing agent, and baked with the Hele-Shaw device master in an oven at 60°C for 12 h. The PDMS was then removed from the master, and inlet and outlet holes were punched with a Harris Uni-Core 1.5 mm biopsy punch. Both the patterned PDMS channel and glass with IDA electrodes were rinsed with acetone, isopropyl alcohol, and DI H₂O, dried with an air gun, cleaned in a Harrick Plasma Cleaner for 60 s, bonded together, and baked in an oven at 60°C for 12 h. IDA electrodes were then connected externally to wires with MG Chemicals 8331 Silver Conductive Epoxy, and inlet and outlet ports were connected to Tygon S-54-HL Microbore tubing.

2.3 Antibody functionalization

Immunocapture experiments were conducted with the humanized monoclonal biotinylated antibody J591 (manufactured by Lonza Biologics plc for BZL Biologics). This antibody has been shown to have high specificity for PSMA [45], and its use in the analysis of immunocapture performance of LNCaPs was characterized over a range of concentrations and shear stresses [46]. Additionally, J591 has been used to demonstrate high-efficiency immunocapture of prostate CTCs from prostate cancer patient blood samples [9, 17]. The glass surface of the Hele-Shaw flow cell was functionalized to immobilize the antibody using MPTMS–GMBS–NeutrAvidin–biotin chemistry following previously reported protocols [17, 46].

2.4 Cell culture maintenance

All experiments were conducted with LNCaPs, an immortalized PSMA-expressing prostate cancer cell line, purchased from the American Type Culture Collection. LNCaPs were

cultured in Corning CellBIND T75 culture flasks at 37°C in a 5% CO₂ humidified environment. Cells were cultured in RPMI-1640 supplemented with 10% fetal bovine serum and 1% penicillin–streptomycin (Mediatech). To prepare for experiments, cells were trypsinized from the culture flasks, enumerated in a Hausser Scientific hemacytometer, and resuspended in one of three buffer solutions to a specified cell suspension density (see Section 2.5).

2.5 DEP characterization of LNCaPs

The expressions for the time-averaged DEP force on a spherical particle in an infinite domain with homogeneous and isotropic complex permittivities are [30, 31] as follows:

$$\langle \mathbf{F}_{\text{DEP}} \rangle = \pi \epsilon_m a^3 \Re(\tilde{f}_{\text{CM}}) \nabla (\mathbf{E}_0 \cdot \mathbf{E}_0), \quad (1)$$

$$\tilde{f}_{\text{CM}} = \frac{\tilde{\epsilon}_p - \tilde{\epsilon}_m}{\tilde{\epsilon}_p + 2\tilde{\epsilon}_m}, \quad (2)$$

where a is the particle radius, $\mathbf{E} = \mathbf{E}_0 \cos(\omega t)$ is the externally applied AC electric field, $\Re(\tilde{f}_{\text{CM}})$ denotes the real part of the Clausius–Mossotti factor, ω is the angular frequency of the electric field, $\tilde{\epsilon} = \epsilon - i\sigma/\omega$ is the complex permittivity, $i = (-1)^{1/2}$, ϵ is the electrical permittivity, σ is the electrical conductivity, and the subscripts p and m denote the particle and the medium, respectively. When $\Re(\tilde{f}_{\text{CM}}) > 0$, pDEP occurs; conversely, when $\Re(\tilde{f}_{\text{CM}}) < 0$, nDEP occurs. The frequency at which $\Re(\tilde{f}_{\text{CM}}) = 0$, that is when the particle transitions from nDEP to pDEP (or vice versa), is called the “crossover” frequency. In our fabricated devices, the electric field above a pair of IDA electrodes (Fig. 1) can be approximated by assuming that the gap between the electrodes is differentially small. The resulting expressions for the electric field and the DEP force on the particle are [50, 51] the following:

$$\mathbf{E} = \frac{V}{\pi r} \hat{\theta}, \quad (3)$$

$$\langle \mathbf{F}_{\text{DEP}} \rangle = \frac{\epsilon_m a^3}{3\pi r^3} \Re(\tilde{f}_{\text{CM}}) V^2 \hat{r}, \quad (4)$$

where $\hat{\theta}$ and \hat{r} are unit vectors in cylindrical coordinates, r is the radial distance from the center of the electrode gap, and V is the applied potential.

The most common DEP approach for isolating cancer cells from blood relies on a binary separation mechanism in which cancer cells and blood cells are actuated in different directions with pDEP and nDEP, respectively, in a specific applied frequency range [33, 35, 39]. To determine what frequency range to use for DEP separation of LNCaPs, we measured their crossover frequency and characterized their DEP response as a function of applied frequency. These experiments used a separate device consisting of IDA electrodes patterned on glass and bonded to a straight channel defined in PDMS with a depth of 50 μm and a width of 250 μm. This device (henceforth referred to as the IDA electrode device)

was fabricated using the same protocol for the Hele-Shaw flow cell as described in Section 2.2, and the IDA electrodes had the same dimensions as detailed in Fig. 1. The IDA electrode device was not functionalized with J591, allowing for immediate release of trapped LNCaPs when the electric field was turned off, and for several DEP characterization experiments to be performed serially in the same device.

In characterizing the DEP response of LNCaPs, three different buffer solutions were used: (i) an isotonic sugar in DI H₂O solution consisting of 9.5% sucrose, 0.3% dextrose, and 0.1% Pluronic F68 (Sigma-Aldrich) with $\sigma_m = 0.7$ mS/m (similar to that used by other researchers [33, 35]), henceforth referred to as the low-conductivity sugar solution, (ii) the same sugar solution with KCl added to produce $\sigma_m = 70$ mS/m, henceforth referred to as the high-conductivity sugar solution, and (iii) PBS diluted 20 times by volume in the low-conductivity sugar solution also to produce $\sigma_m = 70$ mS/m, henceforth referred to as the diluted PBS solution. To determine the crossover frequency range of LNCaPs, the cells were labeled with Calcein AM dye (Molecular Probes), resuspended in each of the three buffer solutions at a density of 1×10^6 cells/mL, drawn into a plastic syringe (Becton Dickinson), manually flowed through the IDA electrode device, and visualized on a Nikon LV100 upright microscope. The electrodes were energized by an Agilent 33200A function generator at 6 V peak to peak (V_{pp}) and frequencies ranging from 10 kHz to 10 MHz. We chose this voltage and frequency range to keep transmembrane loads and cell heating effects minimal, as previously determined by other studies [32]. At each applied frequency, we observed whether the LNCaPs were attracted to (pDEP) or repelled from (nDEP) the electrodes, and determined the frequency range in which the cells were unaffected by the DEP force (i.e. crossover frequency).

We measured the relative magnitude of the pDEP response of LNCaPs as a function of frequency using a previously reported automated DEP characterization process [51]. To summarize, LNCaPs were labeled with Calcein AM, suspended at 1×10^6 cells/mL in each of the three buffer solutions, and flowed through the IDA electrode device at a rate of 0.2 mL/h using a Chemyx Fusion 400 syringe pump. Voltages ranging from 2 to 8 V_{pp} and frequencies ranging from 40 kHz to 10 MHz were applied, and cell trapping on the first five electrodes was visualized on the Nikon LV100 upright microscope and quantified by fluorescence intensity using a custom LabVIEW (National Instruments) interface. A “trapping potential” was extrapolated for each applied frequency using a series of postprocessing analyses in MATLAB (MathWorks). This trapping potential, V_{trap} , was defined as the minimum voltage needed to trap a threshold number of cells (as quantified by fluorescence intensity) to be considered a pDEP response, and was related to the magnitude of the DEP force by $C_0 \Re(f_{CM}) = 1/V_{trap}^2$ (following Eq. (4)), where C_0 denotes an arbitrary constant related to the flow rate and electrode geometry [51]. Therefore, we report our DEP characterization data in terms of C_0/V_{trap}^2 as a function of frequency to describe the proportionate DEP response of LNCaPs.

The pDEP characterization data were fit to a function for $\Re(f_{CM})$ by modeling the LNCaP cell as a single-shelled dielectric sphere. The interaction between the electric field and the cell occurs primarily at the cell membrane, although the physical and electrical properties of the membrane are often difficult to infer from experimental measurements [32]. Therefore, we modeled the electrical properties of the cell in terms of a specific membrane capacitance, $C_{membrane}$, in addition to the cytoplasmic electrical properties [52]. The effective permittivity of the particle, $\tilde{\epsilon}_p$, in Eq. (2) is then replaced by an effective permittivity for the cell, $\tilde{\epsilon}_{cell}$, that is a function of both $C_{membrane}$ and the cytoplasmic permittivity and conductivity [29]:

$$\tilde{\epsilon}_{cell} = \frac{C_{membrane} a \tilde{\epsilon}_{cytoplasm}}{C_{membrane} a + \tilde{\epsilon}_{cytoplasm}} \quad (5)$$

Under our experimental conditions ($\sigma_m \leq 0.7$ mS/m and applied frequencies < 10 MHz), varying the cytoplasmic permittivity and conductivity did not significantly change the magnitude of $\Re(f_{CM})$. Therefore, we fixed their values to $50\epsilon_0$ ($\epsilon_0 = 8.85 \times 10^{-12}$ F/m) and 1000 mS/m, respectively, which are within the range of previously reported values for cancer cells [53, 54]. The cell radius was experimentally measured to be 10 ± 1 μ m and was thus fixed to 10 μ m in the model, leaving $C_{membrane}$ and C_0 as the only free parameters in the $\Re(f_{CM})$ fit for the C_0/V_{trap}^2 versus applied frequency data.

2.6 Immunocapture of LNCaPs with DEP effects

To simulate the range of local shear stresses that cells experience in immunocapture devices and to characterize cell adhesion as a function shear stress, LNCaPs were flowed through the Hele-Shaw flow cell and captured cells were enumerated along the length of the device. For all immunocapture experimental conditions, two separate concentrations of antibody in solution were tested (i.e. incubated in the device): 5 and 10 μ g/mL. The cells were labeled with Calcein AM, suspended at 5×10^5 cells/mL in the diluted PBS solution ($\sigma_m = 70$ mS/m), and flowed through the device at 0.2 mL/h using a Chemyx Fusion 400 syringe pump for 10 min. Six separate conditions for the applied DEP force were tested: 6 V_{pp} at 10 kHz (where nDEP is expected), and 1, 3, 4.5, 6, and 10 V_{pp} at 10 MHz (where pDEP is expected). After each capture experiment, PBS was flowed through the device at 0.2 mL/h for 10 min to wash away any nonadherent cells.

Fluorescent images of captured cells were taken at a 20 \times magnification at a series of predetermined observation sites along the length of the device, as shown in Fig. 1. Cell count values were collected for 11 unique shear stress regions with at least three experimental replicates. For all shear stresses, the reported value corresponds to the shear stress at the immunocapture surface of the device in the center of the imaged area. Because streamlines in the Hele-Shaw flow cell diverge, the effective input density of cells is variable and must be

corrected for—for this geometry, the expected input cell density is inversely proportional to the local shear stress. Thus, the reported captured cell densities are the number of cells imaged in a 1 mm^2 region immediately to either side of the central axis of the device (i.e. with and without IDA electrodes) divided by the shear stress at the region's location (shown in Fig. 2) normalized by the inverse of the shear stress at the entrance of the device (where streamline divergence is minimal). This normalization procedure corrected for the diverging streamlines in the device; the normalized captured cell densities of immunocapture with and without DEP effects were then compared at each reported shear stress.

3 Results and discussion

3.1 DEP characterization of LNCaPs

To determine the AC electric field frequency-dependent DEP response of LNCaPs, we characterized their relative DEP magnitude and crossover frequency regions in a low- and high-conductivity sugar solution as well as in PBS diluted in the low-conductivity sugar solution. The trapping potential was measured and the proportionate DEP response was calculated as a function of frequency, shown in Fig. 3A and B, respectively. We found that for the applied electric fields that were tested (10 kHz to 10 MHz, up to $10 V_{pp}$), the cells exhibited no measurable pDEP response in both sugar solutions and PBS with $\sigma_m > 100 \text{ mS/m}$. Therefore, we minimally diluted both buffer solutions to 70 mS/m, which is two to seven times higher than conductivities used in the majority of DEP cancer cell capture studies [33, 53–55]. We obtained similar DEP characterization data for the high-conductivity sugar solution and diluted PBS solution, which suggests that diluted PBS is an appropriate substitute for the isotonic sugar solution. PBS was chosen as a model for whole blood because both have similar osmolarities, ion concentrations, and conductivities (approximately $\sigma_m = 1000 \text{ mS/m}$). Although blood is generally classified as a shear-thinning fluid with a higher viscosity than PBS, we expect that these hydrodynamic differences will discernibly impact the capture performance on a 2D immunocapture surface (e.g. Hele-Shaw flow cell), but minimally impact a 3D immunocapture device (e.g. GEDI [9, 17]) that more heavily relies on cell-to-post collisions for high-efficiency capture. Because we have demonstrated that cancer cells can be actuated by DEP in minimally diluted PBS, we expect to obtain similar results in minimally diluted blood, which can potentially result in a significantly higher throughput than current DEP devices used for rare cancer cell capture from blood.

The DEP response of LNCaPs measured in this work is qualitatively similar to that of cancer cells measured by other research groups [33, 36, 54]. Figure 3A shows that in the tested frequency range, the trapping potential decreased with increasing frequency, that is less voltage was needed to trap cells at higher frequencies. This trend suggests that the DEP response of the cells was stronger at higher frequencies,




Figure 3. Trapping potential (V_{trap}), (A), and proportionate DEP response (C_0/V_{trap}^2), (B), as a function of applied cyclic frequency for LNCaPs suspended in three buffer solutions: (i) an isotonic sugar solution with $\sigma_m = 0.7 \text{ mS/m}$ (squares), (ii) the same sugar solution with KCl added to produce $\sigma_m = 70 \text{ mS/m}$ (diamonds), and (iii) PBS diluted 20 times by volume in the low-conductivity sugar solution to also produce $\sigma_m = 70 \text{ mS/m}$ (triangles). Each value represents the mean of three to seven experimental replicates. Error bars are omitted for clarity; SEM values ranged from 0.2 to $4.6 V_{pp}$ for V_{trap} and 0.008 to $0.2 V_{pp}^{-2}$ for C_0/V_{trap}^2 . Curve fits for $\Re(\tilde{f}_{CM})$ in (B) were calculated using Eqs. (2) and (5). Fit parameters were $C_{\text{membrane}} = 0.15 \text{ mF/m}^2$ and $C_0 = 0.13$ for the low-conductivity sugar solution (solid line), $C_{\text{membrane}} = 5 \text{ mF/m}^2$ and $C_0 = 0.05$ for the high-conductivity sugar solution (dashed line), and $C_{\text{membrane}} = 4 \text{ mF/m}^2$ and $C_0 = 0.04$ for the diluted PBS solution (dotted line).

as confirmed in the proportionate DEP response data shown in Fig. 3B. A decrease in solution conductivity corresponded to a shift to lower frequencies in both the V_{trap} data and the $\Re(\tilde{f}_{CM})$ curve fits; this shift was most clearly demonstrated in our crossover frequency measurements: approximately 300 kHz for $\sigma_m = 70 \text{ mS/m}$ and 100 kHz for $\sigma_m = 0.7 \text{ mS/m}$. Despite this shift in frequency response, the trapping potential remained in the same range for both conductivities (Fig. 3A), suggesting that the maximum value of $\Re(\tilde{f}_{CM})$ was comparable in both cases. Wu et al. reported similar trends in their capture voltage spectrum data for colorectal cancer

cells, and obtained crossover frequencies in the same range using sucrose buffer solutions with $\sigma_m = 50$ and 100 mS/m [36].

The curve fits for $\Re(\tilde{f}_{CM})$ in Fig. 3B were calculated by modeling the LNCaP cell as a single-shelled dielectric sphere with a frequency-dependent DEP response primarily dictated by a specific membrane capacitance, $C_{membrane}$ [52]. In the high-conductivity cases, the pDEP response and crossover frequency regions were fit well; the magnitude and frequency dependence, as well as the fit value for $C_{membrane}$, were similar to those previously reported for other cancer cells [54–56]. Yang et al. reported on DEP separation of LNCaPs from colorectal cancer cells, but used a higher conductivity media ($\sigma_m = 300$ mS/m) at which LNCaPs experienced nDEP even in the MHz range [44]. Although we did not perform DEP characterization experiments at this conductivity, our model does predict similar nDEP behavior in those high conductivity and frequency ranges.

In the low-conductivity sugar solution, however, the best fit for $C_{membrane}$ and the measured crossover frequency resulted in a predicted $\Re(\tilde{f}_{CM})$ that was lower in magnitude than the other curve fits; this difference was not seen in the trapping potential values measured for both conductivities. Thus, the single-shell dielectric model seems able to describe only some aspects of the data. Despite this drawback, the model accurately predicted the DEP response of cancer cells suspended in media with $\sigma_m > 1$ mS/m (as experimentally verified in this study and others [33,39,54]), a range that includes whole blood, the suspending medium of most direct relevance for any CTC capture system. In this study, we measured the proportionate frequency-dependent pDEP response of LNCaPs, their crossover frequency, and predicted nDEP frequency range. Importantly, we obtained the strong pDEP response of LNCaPs by only diluting PBS by 20 times (in contrast to typical 100- to 1000-fold dilutions done by other researchers [33, 35, 39]). These results inform the design of future hybrid DEP-immunocapture systems for CTC isolation that, if multiplexed, have the potential to produce comparable capture efficiencies to existing immunocapture techniques (e.g. GEDI [9, 17]), with enhanced capture purity from the addition of DEP effects.

3.2 Immunocapture of LNCaPs with DEP effects

To study the effect of antibody concentration on immunocapture with and without DEP, we performed capture experiments in a microfluidic device of uniform, shallow depth (i.e. a Hele-Shaw flow cell) that was functionalized with two J591 incubating solution concentrations: 5 and $10 \mu\text{g/mL}$. In both cases, a range of voltages and frequencies were applied, and captured LNCaPs in regions up to 1 mm to either side of the device's central axis (i.e. regions with and without IDA electrodes) were enumerated across a range of shear stresses. Figure 4 shows the calculated mean ratio of captured cell density with and without DEP effects across the entire range of




Figure 4. Ratio of captured cell density (normalized for streamline divergence) with and without DEP effects under various applied electric field frequency and voltage conditions for two J591 incubating solution concentrations: $5 \mu\text{g/mL}$ (circles) and $10 \mu\text{g/mL}$ (triangles). Ratios were averaged over captured cell density values across all shear stresses listed in Table 1. The no-DEP condition had 22 experimental replicates for the $10 \mu\text{g/mL}$ case and 15 replicates for the $5 \mu\text{g/mL}$ case; all other conditions had three to seven replicates. Error bars represent SEM of ratios calculated at 11 shear stress values. The abscissa is plotted as $\Re(\tilde{f}_{CM})V^2$, which is proportional to the DEP force (Eq. (4)), to differentiate between nDEP and pDEP conditions. V was the applied voltage, and the values of $\Re(\tilde{f}_{CM}) = -0.5$ at 10 kHz and $\Re(\tilde{f}_{CM}) = 0.8$ at 10 MHz were obtained from the curve fits shown in Fig. 3B.

shear stresses. As expected, there were fewer cells captured when an nDEP force was applied (ratio lower than 1), and more cells captured with an increasing pDEP force (ratio close to 1 when $1 V_{pp}$ was applied, and growing with increasing applied voltage). In comparing the two antibody incubating solution concentrations, when nDEP was applied at 10 kHz, fewer cells were repelled from the immunocapture surface in the $10 \mu\text{g/mL}$ case, thus resulting in a higher ratio of captured cell density with and without DEP. Furthermore, DEP-enhanced immunocapture at 10 MHz saturated for voltages above $4.5 V_{pp}$ with $10 \mu\text{g/mL}$, whereas capture performance continued to improve up to $6 V_{pp}$ with $5 \mu\text{g/mL}$. These results suggest that the immunocapture surface was saturated with antibody in the $10 \mu\text{g/mL}$ case (consistent with our previously reported results [46]). Although we demonstrated that the two antibody concentrations resulted in similar trends of immunocapture with and without DEP effects, the difference in capture performance is more evident with the lower concentration. Therefore, we only further analyzed and present data from the $5 \mu\text{g/mL}$ case.

The captured cell density was quantified over a range of shear stress values for two applied frequencies (one of each chosen to induce pDEP or nDEP) and a series of increasing applied voltages; these values are listed in Table 1. We also performed experiments at 10 MHz with $10 V_{pp}$, but found that the pDEP force was so strong that nearly all LNCaPs were captured at the first few electrodes nearest to the inlet, invalidating the weak-capture assumption required to interpret the data. The $10 V_{pp}$ data are thus omitted. Figure 5

Table 1. Captured cell density (normalized for streamline divergence) with a J591 incubating solution concentration of 5 $\mu\text{g}/\text{mL}$ under various applied electric field frequency and voltage conditions as a function of shear stress.

Shear stress (Pa)	Captured cell density (cells/ mm^2)					
	No DEP	10 kHz, 6 V_{pp}	10 MHz, 1 V_{pp}	10 MHz, 3 V_{pp}	10 MHz, 4.5 V_{pp}	10 MHz, 6 V_{pp}
0.009	123.9 \pm 70.1	44.8 \pm 20.3	151.3 \pm 140.5	147.9 \pm 105.9	263.3 \pm 80.8	227.5 \pm 146.4
0.011	71.1 \pm 35.3	34.1 \pm 36.9	93.7 \pm 87.7	133.8 \pm 66.7	142.3 \pm 37.2	195.9 \pm 147.3
0.013	53.1 \pm 25.0	18.7 \pm 6.6	64.1 \pm 50.4	104.4 \pm 51.8	85.7 \pm 17.5	103.7 \pm 58.4
0.015	44.4 \pm 24.3	13.4 \pm 8.3	35.7 \pm 25.2	79.7 \pm 46.8	49.1 \pm 9.8	63.7 \pm 18.9
0.017	33.6 \pm 13.9	15.0 \pm 4.0	24.2 \pm 12.5	49.6 \pm 22.2	41.5 \pm 22.6	61.1 \pm 25.9
0.018	23.6 \pm 11.6	14.4 \pm 7.3	19.1 \pm 3.2	35.6 \pm 20.7	29.2 \pm 5.6	36.1 \pm 17.5
0.020	21.1 \pm 7.2	10.8 \pm 0.8	15.2 \pm 10.0	27.0 \pm 2.2	22.1 \pm 3.9	37.8 \pm 8.6
0.021	18.9 \pm 6.6	10.9 \pm 5.5	12.7 \pm 11.9	19.6 \pm 11.4	21.4 \pm 10.3	28.2 \pm 4.2
0.023	17.9 \pm 7.5	13.6 \pm 1.9	17.0 \pm 7.2	20.0 \pm 8.1	20.0 \pm 1.9	27.6 \pm 1.5
0.024	18.7 \pm 8.0	16.3 \pm 8.8	12.0 \pm 7.3	17.1 \pm 7.7	17.9 \pm 7.3	17.9 \pm 5.5
0.026	17.4 \pm 6.9	16.2 \pm 9.1	18.8 \pm 8.8	16.6 \pm 7.5	14.7 \pm 4.1	11.7 \pm 5.1

Captured cell density is reported as mean \pm SD. The no-DEP condition had 15 experimental replicates; all other conditions had three replicates.




Figure 5. Captured cell density (normalized for streamline divergence) as a function of shear stress under representative cases of pDEP (10 MHz, 6 V_{pp} ; black bars), nDEP (10 kHz, 6 V_{pp} ; gray bars), and no DEP (white bars). Bars represent the mean captured cell density for the corresponding data listed in Table 1. The no-DEP condition had 15 experimental replicates; the pDEP and nDEP conditions had three replicates each. Error bars represent SD.

shows representative cases of captured cell density with pDEP (10 MHz, 6 V_{pp}), nDEP (10 kHz, 6 V_{pp}), and no DEP applied. The observed trend of immunocapture with no DEP effects as a function of shear stress is consistent with those previously reported for LNCaPs [46]. In general, the number of captured cells increased with increasing applied voltage (i.e. pDEP force), and decreased with increasing shear stress. Immunocapture was enhanced by pDEP at 10 MHz, and was diminished by nDEP at 10 kHz. This trend is observed over nearly the entire shear stress range; at the two highest shear stress values, however, the captured cell densities with and without DEP were comparable, suggesting that immunocapture performance was both poor and unaffected by DEP above a threshold shear stress. Although we present a quantitative comparison of immunocapture with and without DEP effects as a function of shear stress, the underlying mechanisms of shear-dependent cell adhesion and rolling have been described using more complex models by other researchers [57, 58].

To our knowledge, this is the first reported study of DEP effects on the immunocapture of cancer cells. Our results provide insight on the experimental conditions (e.g. applied voltage range, antibody concentration, flow parameters, and device geometries that control shear stress) needed to optimize DEP-guided immunocapture performance. From a technology standpoint, this work was completed with a device that was designed to generate shear-dependent adhesion data [46]; we focused on characterization of cell physicochemical response rather than clinical and translational implementation of high-efficiency rare cell capture, which we have reported previously [9]. Our data on shear-dependent cell adhesion with the addition of DEP effects can be incorporated into computational fluid dynamics simulations of cancer and blood cell trajectories in 3D immunocapture devices to better predict capture performance and inform the design of future high-purity CTC capture systems that can facilitate subsequent clinical studies [17, 27].

Previous studies have also reported the combination of DEP with a variety of other techniques to enable cell capture, separation, or characterization. Yang et al. combined DEP and immunocapture to detect and concentrate *Listeria* and *Salmonella* cells [59, 60], Kim et al. demonstrated DEP-magnetic activated sorting of bacteria and cancer cells [41, 61], Hashimoto et al. selectively captured leukocytes using nDEP to direct cells to antibody-immobilized regions [62], and Cristofanilli et al. used DEP to separate cancer cells on an “electrosmeared” slide with adhesive coating [63]. In addition, DEP has been used for anticancer drug screening [64], detection of cancer markers [65], and impedance sensing of cancer cells [66]. For applications in rare CTC capture from whole blood, however, DEP may best complement existing robust immunocapture techniques that demonstrate antigen specificity and high-efficiency capture [17]. A hybrid DEP-immunocapture system in which DEP is tuned to promote CTC interactions (by pDEP) and prevent leukocyte interactions (by nDEP) with capture surfaces can minimize problems associated with immunocapture techniques, such

as nonspecific leukocyte adhesion. Such a DEP-guided immunocapture system has the potential to be used in high-impact clinical studies (e.g. genetic and pharmacological evaluation of CTCs [9]) that benefit from the platform's improved CTC capture efficiency and purity relative to either DEP or immunocapture techniques alone.

4 Concluding remarks

This work characterizes shear-dependent cancer cell adhesion in a novel hybrid DEP–immunocapture microfluidic system. We measured the frequency-dependent pDEP response of LNCaPs, as well as their crossover frequency and nDEP frequency ranges. We showed that, depending on the applied frequency, DEP can control the capture performance of prostate cancer cells by attracting them to or repelling them from immunocapture surfaces, and that this phenomenon is dependent on local shear stresses experienced by the cells. In designing future CTC capture devices, we expect that DEP and immunocapture techniques will work synergistically to yield improved capture performance and facilitate subsequent biological studies on CTCs.

This work was supported by the Center on the Microenvironment and Metastasis at Cornell (award number U54CA-143876) from the National Cancer Institute Physical Sciences Oncology Center (NCI PS-OC). CH and BGH were supported by National Science Foundation (NSF) Graduate Research Fellowships, and SMS was supported by Cornell's Learning Initiative in Medicine and Bioengineering (CLIMB) NSF GK-12 program and a Cornell Sloan Fellowship. Device fabrication was performed in part at the Cornell NanoScale Science and Technology Facility (CNF), a member of the National Nanotechnology Infrastructure Network, which is supported by the NSF (Grant ECS-0335765). The authors thank Erica D. Pratt and Srinitya Arasanipalai for helpful discussions.

The authors have declared no conflict of interest.

5 References

- [1] Allard, W. J., Matera, J., Miller, M. C., Repollet, M., Connelly, M. C., Rao, C., Tibbe, A. G. J., Uhr, J. W., Terstappen, L. W. M. M., *Clin. Cancer Res.* 2004, **10**, 6897–6904.
- [2] Maheswaran, S., Haber, D. A., *Curr. Opin. Genet. Dev.* 2010, **20**, 96–99.
- [3] Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., Hayes, D. F., *N. Engl. J. Med.* 2004, **351**, 781–791.
- [4] Hayes, D. F., Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Miller, M. C., Matera, J., Allard, W. J., Doyle, G. V., Terstappen, L. W. M. M., *Clin. Cancer Res.* 2006, **12**, 4218–4224.
- [5] de Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., Doyle, G. V., Terstappen, L. W. M. M., Pienta, K. J., Raghavan, D., *Clin. Cancer Res.* 2008, **14**, 6302–6309.
- [6] Danila, D. C., Fleisher, M., Scher, H. I., *Clin. Cancer Res.* 2011, **17**, 3903–3912.
- [7] Leversha, M. A., Han, J., Asgari, Z., Danila, D. C., Lin, O., Gonzalez-Espinoza, R., Anand, A., Lilja, H., Heller, G., Fleisher, M., Scher, H. I., *Clin. Cancer Res.* 2009, **15**, 2091–2097.
- [8] Stott, S. L., Lee, R. J., Nagrath, S., Yu, M., Miyamoto, D. T., Ulkus, L., Inserra, E. J., Ulman, M., Springer, S., Nakamura, Z., Moore, A. L., Tsukrov, D. I., Kempner, M. E., Dahl, D. M., Wu, C.-L., Iafrate, A. J., Smith, M. R., Tompkins, R. G., Sequist, L. V., Toner, M., Haber, D. A., Maheswaran, S., *Sci. Transl. Med.* 2010, **2**, 25ra23.
- [9] Kirby, B. J., Jodari, M., Loftus, M. S., Gakhar, G., Pratt, E. D., Chanel-Vos, C., Gleghorn, J. P., Santana, S. M., Liu, H., Smith, J. P., Navarro, V. N., Tagawa, S. T., Bander, N. H., Nanus, D. M., Giannakakou, P., *PLoS One* 2012, **7**, e35976.
- [10] Rhim, A. D., Mirek, E. T., Aiello, N. M., Maitra, A., Bailey, J. M., McAllister, F., Reichert, M., Beatty, G. L., Rustgi, A. K., Vonderheide, R. H., Leach, S. D., Stanger, B. Z., *Cell* 2012, **148**, 349–361.
- [11] Yu, M., Ting, D. T., Stott, S. L., Wittner, B. S., Ozsolak, F., Paul, S., Ciciliano, J. C., Smas, M. E., Winokur, D., Gilman, A. J., Ulman, M. J., Xega, K., Contino, G., Alagesan, B., Brannigan, B. W., Milos, P. M., Ryan, D. P., Sequist, L. V., Bardeesy, N., Ramaswamy, S., Toner, M., Maheswaran, S., Haber, D. A., *Nature* 2012, **487**, 510–513.
- [12] Racila, E., Euhus, D., Weiss, A. J., Rao, C., McConnell, J., Terstappen, L. W. M. M., Uhr, J. W., *Proc. Natl. Acad. Sci. USA* 1998, **95**, 4589–4594.
- [13] Krivacic, R. T., Ladanyi, A., Curry, D. N., Hsieh, H. B., Kuhn, P., Bergsrud, D. E., Kepros, J. F., Barbera, T., Ho, M. Y., Chen, L. B., Lerner, R. A., Bruce, R. H., *Proc. Natl. Acad. Sci. USA* 2004, **101**, 10501–10504.
- [14] Pratt, E. D., Huang, C., Hawkins, B. G., Gleghorn, J. P., Kirby, B. J., *Chem. Eng. Sci.* 2011, **66**, 1508–1522.
- [15] Parkinson, D. R., Dracopoli, N., Gumbs Petty, B., Compton, C., Cristofanilli, M., Deisseroth, A., Hayes, D. F., Kapke, G., Kumar, P., Lee, J. S., Liu, M. C., McCormack, R., Mikulski, S., Nagahara, L., Pantel, K., Pearson-White, S., Punnoose, E. A., Roadcap, L. T., Schade, A. E., Scher, H. I., Sigman, C. C., Kelloff, G. J., *J. Transl. Med.* 2012, **10**, 138.
- [16] Nagrath, S., Sequist, L. V., Maheswaran, S., Bell, D. W., Irimia, D., Ulkus, L., Smith, M. R., Kwak, E. L., Digumarthy, S., Muzikansky, A., Ryan, P., Balis, U. J., Tompkins, R. G., Haber, D. A., Toner, M., *Nature* 2007, **450**, 1235–1239.
- [17] Gleghorn, J. P., Pratt, E. D., Denning, D., Liu, H., Bander, N. H., Tagawa, S. T., Nanus, D. M., Giannakakou, P. A., Kirby, B. J., *Lab Chip* 2010, **10**, 27–29.
- [18] Stott, S. L., Hsu, C.-H., Tsukrov, D. I., Yu, M., Miyamoto, D. T., Waltman, B. A., Rothenberg, S. M., Shah, A. M., Smas, M. E., Korir, G. K., Floyd, F. P., Gilman, A. J., Lord, J. B., Winokur, D., Springer, S., Irimia, D., Nagrath, S., Sequist, L. V., Lee, R. J., Isselbacher, K. J., Maheswaran, S., Haber, D. A., Toner, M., *Proc. Natl. Acad. Sci. USA* 2010, **107**, 18392–18397.
- [19] Wang, S., Liu, K., Liu, J., Yu, Z. T.-F., Xu, X., Zhao, L., Lee, T., Lee, E. K., Reiss, J., Lee, Y.-K., Chung, L. W. K.,

- Huang, J., Rettig, M., Seligson, D., Duraiswamy, K. N., Shen, C. K.-F., Tseng, H.-R., *Angew. Chem. Int. Ed.* 2011, 50, 3084–3088.
- [20] Zheng, S., Lin, H., Liu, J.-Q., Balic, M., Datar, R., Cote, R. J., Tai, Y.-C., *J. Chromatogr. A* 2007, 1162, 154–161.
- [21] Lin, H. K., Zheng, S., Williams, A. J., Balic, M., Groshen, S., Scher, H. I., Fleisher, M., Stadler, W., Datar, R. H., Tai, Y.-C., Cote, R. J., *Clin. Cancer Res.* 2010, 16, 5011–5018.
- [22] Adams, A. A., Okagbare, P. I., Feng, J., Hupert, M. L., Patterson, D., Göttert, J., McCarley, R. L., Nikitopoulos, D., Murphy, M. C., Soper, S. A., *J. Am. Chem. Soc.* 2008, 130, 8633–8641.
- [23] Dharmasiri, U., Njoroge, S. K., Witek, M. A., Adebisi, M. G., Kamande, J. W., Hupert, M. L., Barany, F., Soper, S. A., *Anal. Chem.* 2011, 83, 2301–2309.
- [24] Hughes, A. D., King, M. R., *Langmuir* 2010, 26, 12155–12164.
- [25] Hughes, A. D., Mattison, J., Western, L. T., Powderly, J. D., Greene, B. T., King, M. R., *Clin. Chem.* 2012, 58, 846–853.
- [26] Wang, S., Wang, H., Jiao, J., Chen, K.-J., Owens, G. E., Kamei, K.-I., Sun, J., Sherman, D. J., Behrenbruch, C. P., Wu, H., Tseng, H.-R., *Angew. Chem. Int. Ed.* 2009, 48, 8970–8973.
- [27] Smith, J. P., Barbati, A. C., Santana, S. M., Gleghorn, J. P., Kirby, B. J., *Electrophoresis* 2012, 33, 3133–3142.
- [28] Hawkins, B. G., Gleghorn, J. P., Kirby, B. J., Zahn, J. D. (Eds.), *Methods in Bioengineering: Biomicrofabrication and Biomicrofluidics*, Artech House, Boston 2009, pp. 133–181.
- [29] Jones, T. B., *Electromechanics of Particles*, Cambridge University Press, New York 1995.
- [30] Morgan, H., Green, N., *AC Electrokinetics: Colloids and Nanoparticles*, Research Studies Press, Ltd., Baldock, Hertfordshire, England 2002.
- [31] Kirby, B. J., *Micro- and Nanoscale Fluid Mechanics: Transport in Microfluidic Devices*, Cambridge University Press, New York 2010.
- [32] Voldman, J., *Annu. Rev. Biomed. Eng.* 2006, 8, 425–454.
- [33] Gascoyne, P. R. C., Noshari, J., Anderson, T. J., Becker, F. F., *Electrophoresis* 2009, 30, 1388–1398.
- [34] Shim, S., Gascoyne, P., Noshari, J., Hale, K. S., *Integr. Biol.* 2011, 3, 850–862.
- [35] Gupta, V., Jafferji, I., Garza, M., Melnikova, V. O., Hasegawa, D. K., Pethig, R., Davis, D. W., *Biomicrofluidics* 2012, 6, 024133.
- [36] Wu, L., Lanry Yung, L.-Y., Lim, K.-M., *Biomicrofluidics* 2012, 6, 14113.
- [37] Bhattacharya, S., Chao, T.-C., Ros, A., *Electrophoresis* 2011, 32, 2550–2558.
- [38] Shafiee, H., Sano, M. B., Henslee, E. A., Caldwell, J. L., Davalos, R. V., *Lab Chip* 2010, 10, 438–445.
- [39] Henslee, E. A., Sano, M. B., Rojas, A. D., Schmelz, E. M., Davalos, R. V., *Electrophoresis* 2011, 32, 2523–2529.
- [40] Salmanzadeh, A., Romero, L., Shafiee, H., Gallo-Villanueva, R. C., Stremmler, M. A., Cramer, S. D., Davalos, R. V., *Lab Chip* 2012, 12, 182–189.
- [41] Kim, U., Shu, C.-W., Dane, K. Y., Daugherty, P. S., Wang, J. Y. J., Soh, H. T., *Proc. Natl. Acad. Sci. USA* 2007, 104, 20708–20712.
- [42] Alazzam, A., Stiharu, I., Bhat, R., Meguerditchian, A.-N., *Electrophoresis* 2011, 32, 1327–1336.
- [43] Moon, H.-S., Kwon, K., Kim, S.-I., Han, H., Sohn, J., Lee, S., Jung, H.-I., *Lab Chip* 2011, 11, 1118–1125.
- [44] Yang, F., Yang, X., Jiang, H., Wang, G., *Electrophoresis* 2011, 32, 2377–2384.
- [45] Liu, H., Moy, P., Kim, S., Xia, Y., Rajasekaran, A., Navarro, V., Knudsen, B., Bander, N. H., *Cancer Res.* 1997, 57, 3629–3634.
- [46] Santana, S. M., Liu, H., Bander, N. H., Gleghorn, J. P., Kirby, B. J., *Biomed. Microdevices* 2012, 14, 401–407.
- [47] Usami, S., Chen, H. H., Zhao, Y., Chien, S., Skalak, R., *Ann. Biomed. Eng.* 1993, 21, 77–83.
- [48] Sethu, P., Sin, A., Toner, M., *Lab Chip* 2006, 6, 83–89.
- [49] Murthy, S. K., Sin, A., Tompkins, R. G., Toner, M., *Langmuir* 2004, 20, 11649–11655.
- [50] Sanchis, A., Brown, A. P., Sancho, M., Martínez, G., Sebastián, J. L., Muñoz, S., Miranda, J. M., *Bioelectromagnetics* 2007, 28, 393–401.
- [51] Hawkins, B. G., Huang, C., Arasanipalai, S., Kirby, B. J., *Anal. Chem.* 2011, 83, 3507–3515.
- [52] Foster, K. R., Sauer, F. A., Schwan, H. P., *Biophys. J.* 1992, 63, 180–190.
- [53] Becker, F. F., Gascoyne, P. R., Wang, X. B., Huang, Y., Pethig, R., Vykoukal, J., *Proc. Natl. Acad. Sci. USA* 1995, 92, 860–864.
- [54] Sano, M. B., Henslee, E. A., Schmelz, E., Davalos, R. V., *Electrophoresis* 2011, 32, 3164–3171.
- [55] Huang, Y., Yang, J., Wang, X. B., Becker, F. F., Gascoyne, P. R. C., *J. Hematother. Stem Cell* 1999, 8, 481–90.
- [56] Mulhall, H. J., Labeed, F. H., Kazmi, B., Costea, D. E., Hughes, M. P., Lewis, M. P., *Anal. Bioanal. Chem.* 2011, 401, 2455–2463.
- [57] Hammer, D. A., Lauffenburger, D. A., *Biophys. J.* 1987, 52, 475–487.
- [58] Caputo, K. E., Lee, D., King, M. R., Hammer, D. A., *Biophys. J.* 2007, 92, 787–797.
- [59] Yang, L., Banada, P. P., Chatni, M. R., Seop Lim, K., Bhunia, A. K., Ladisch, M., Bashir, R., *Lab Chip* 2006, 6, 896–905.
- [60] Yang, L., *Talanta* 2009, 80, 551–558.
- [61] Kim, U., Soh, H. T., *Lab Chip* 2009, 9, 2313–2318.
- [62] Hashimoto, M., Kaji, H., Nishizawa, M., *Biosens. Bioelectron.* 2009, 24, 2892–2897.
- [63] Cristofanilli, M., Krishnamurthy, S., Das, C. M., Reuben, J. M., Spohn, W., Noshari, J., Becker, F., Gascoyne, P. R., *J. Sep. Sci.* 2008, 31, 3732–3739.
- [64] Hsiung, L.-C., Chiang, C.-L., Wang, C.-H., Huang, Y.-H., Kuo, C.-T., Cheng, J.-Y., Lin, C.-H., Wu, V., Chou, H.-Y., Jong, D.-S., Lee, H., Wo, A. M., *Lab Chip* 2011, 11, 2333–2342.
- [65] Ramón-Azcón, J., Yasukawa, T., Mizutani, F., *Biosens. Bioelectron.* 2011, 28, 443–449.
- [66] Chuang, C.-H., Huang, Y.-W., Wu, Y.-T., *Sensors* 2011, 11, 11021–11035.